SUNET harnesses Adtran’s ALM fiber monitoring solution for national backbone network
28.5.2024 15:00:00 EEST | Business Wire | Press release
Adtrantoday announced that the Swedish University Computer Network (SUNET) has deployed its ALM in-service fiber monitoring solution to enhance network resilience and operational efficiency. The technology equips SUNET’s maintenance teams with real-time insight into the quality of its nationwide backbone infrastructure and identifies the precise location of any fiber issues. As Sweden’s research and education (R&E) network, SUNET empowers academics and scientists across the country to access learning resources, conduct research and collaborate internationally. With the deployment of ALM, the Nordics’ R&E community has additional assurance of uninterrupted, high-quality services. NetNordic, a key technology partner of SUNET, was also involved in the deployment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528454910/en/
Adtran’s ALM is helping SUNET monitor its national fiber network to rapidly identify faults and support swift resolution. (Photo: Business Wire)
“SUNET is a world-class high-capacity optical transport network connecting over 110 organizations and serving a community of 750,000 students, teachers and researchers across Sweden and beyond. The deployment of our ALM platform, with its passive fiber monitoring capabilities, has built even more resilience into this crucially important infrastructure, rendering services more reliable and streamlining operations,” said Stuart Broome, GM of EMEA sales at Adtran. “Finding the exact location of faults is a huge challenge for any operator. But now, with the ability to monitor the integrity of its fiber plant passively and proactively, SUNET’s maintenance teams no longer have to engage in costly and complicated post-failure analysis. ALM enables them to address issues before they impact the high-bandwidth, low-latency services Sweden’s R&E community relies on.”
The deployment of Adtran’s 16-port ALM fiber assurance solution across SUNET’s extensive fiber 8,000km backbone network enables rapid identification and resolution of failures, enhancing network resilience. This is a crucial advantage for a user community involved in data-heavy scientific research. The technology also helps improve efficiency by enabling proactive maintenance. Through an intuitive graphical user interface, SUNET can leverage ALM to monitor a vast national infrastructure containing RAMAN-amplified optical links. The platform detects abnormal attenuation, fiber breaks, tapping attempts and other issues that have the potential to impact connection quality and service availability. ALM also boosts sustainability by cutting down on truck rolls, while its low power use and fanless design ensure a greener, less resource-heavy network.
“From climate science to engineering to medicine, SUNET supports a wide range of important data-intensive projects. That’s why its infrastructure needs to be both fast and highly reliable. Our ALM technology guarantees peak network efficiency and resilience against unpredictable challenges like excavation damage or severe storms. With 24/7 monitoring capabilities, it enables SUNET’s maintenance teams to quickly identify and rectify any issues, ensuring uninterrupted, high-quality service,” commented Sander Jansen, GM of infrastructure monitoring at Adtran. “Moreover, our technology enhances environmental sustainability by reducing unnecessary site visits and lowering carbon footprint. This creates a network that benefits not just today’s users but also future generations.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
About SUNET
SUNET, the Swedish University Computer Network, has served the Swedish universities and other organizations closely related to research and education for more than 40 years. We provide the connected organizations with access to well-developed and effective national and international data communication, a national academic identity infrastructure and other related services that meet their needs, regardless of their geographical location. We are part of the Swedish Research Council and connect Sweden through 8400 km of nationwide dark fiber. For more information, please visit www.sunet.se.
Published by
ADTRAN Holdings, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528454910/en/
Contact information
For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com
For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
